Enough: Your Health, Your Weight, and What It's Like to Be Free

Oprah Winfrey, Ania M. Jastreboff

52 pages 1-hour read

Oprah Winfrey, Ania M. Jastreboff

Enough: Your Health, Your Weight, and What It's Like to Be Free

Nonfiction | Book | Adult | Published in 2026

A modern alternative to SparkNotes and CliffsNotes, SuperSummary offers high-quality Study Guides with detailed chapter summaries and analysis of major themes, characters, and more.

Chapters 6-8Chapter Summaries & Analyses

Content Warning: This section of the guide includes discussion of illness, mental illness, and disordered eating.

Chapter 6 Summary & Analysis: “Enough Is Enough (Finally): Starting the Medications”

Jastreboff considers the development of these new obesity medications a watershed moment in medical history, once more advocating for The Medical Necessity of Treating Obesity. The two treatments are semaglutide and tirzepatide. After the SURMOUNT-1 findings, interest in these treatments exploded, as half of Americans qualify for a prescription. However, their initial release was not without its problems. The high demand for these drugs led to shortages fairly quickly, and as a result, people with diabetes struggled to access the medications essential for the management of their own condition (Awan, Omer. “Ozempic Is in Short Supply. Here’s How That Affects Diabetics.” Forbes, 25 Aug. 2024). 


The dosage was also an issue. The medications are given as an injectable, and many were packaged as single-dose injectables, meaning that everyone received the same amount. This led to side effects in patients who should have started at lower dosages. To make matters worse, some insurance companies initially covered the treatments and then stopped, abruptly leaving some patients without their medication. Jastreboff expresses her frustration that these people had to stop treatment and subsequently regained the weight they had lost when using the drugs.


Obesity medications are made with synthetic, lab-produced hormones that deliver higher and longer lasting hormone doses than the body would naturally. Jastreboff compares hormones to “keys” that fit into certain “locks,” or receptors. By making durable peptides that can withstand the body’s DPP-4 enzyme, which breaks down these kinds of hormones, scientists have made NuSH-based medications that can last for about 5-7 days in the body. With these synthetic hormones at work, the brain cues the body that it has enough fuel and can stop eating. As a result, patients feel fuller and more satisfied and are less likely to struggle with cravings and overeating. 


However, Jastreboff claims that when patients stop taking these medications, their bodies immediately revert to their old Enough Point, and the old symptoms return. She thus advocates for treating medication as a permanent solution, which in turn means that patients would have to be comfortable with risking serious side effects for the rest of their lives, not just for a temporary period. This framing raises the stakes considerably for patients considering these medications, but Jastreboff does not seriously address the trade-offs inherent in courting these risks over many years or decades, nor does she acknowledge the concern that such risks might increase with sustained use. 


While Jastreboff does clarify that there are always risks when taking a new medication and admits that it is impossible to completely eliminate risks to patients, she nonetheless continues to present obesity as a “problem” that should be “solved” at any cost. This stance once more frames her analysis in rather uncompromising terms. She claims that she and her patients carefully weigh the risks of not treating their obesity with the risks of using obesity medications. She also reminds readers that there are over 200 obesity-related conditions, including diabetes, arguing that there may be high risks involved in not treating severe obesity. However, she does not present any case studies of patients who decided to forego the risks of the medications, and she does not enumerate the factors that could lead to such a conclusion. She also does not present any case studies in which a patient did try the medications but experienced severe side effects as a result. 


Jastreboff instead tries to persuade the readers by using an anecdote about convincing a skeptical patient. She points to one patient, Yolanda, who was hesitant to try injectable medications. She had a fear of needles and was scared of the possible side effects of nausea and gallstones (which are among the milder possible side effects). After weighing her options with Jastreboff, Yolanda overcame her fears and tried the medication. In the end, she experienced no side effects and successfully lost weight. Winfrey recalls how she was also hesitant to begin obesity medications. She found it strange and scary to inject something into her stomach and also felt that such a method was “cheating.” Looking back now, she feels that she was being close-minded and stubborn, and she is glad she changed her mind and tried the medication. Again, the authors offer no case studies that offer counterpoints or negative experiences, which creates a limited portrait of these medications and patient results. 


Jastreboff explains that the two obesity medications, semaglutide and tirzepatide, have been branded into different products. Zepbound and Mounjaro are tirzepatide, while Wegovy, Ozempic, and Rybelsus are semaglutide. While these medications are currently only available in injectable form, the Jastreboff is hopeful that there will be chewable versions in the future, making them easier to take. The author reports that trying different medications, while closely supervised by a doctor, can help people lose weight and avoid the consequences of obesity-related diseases. She recalls treating a patient with the “old” medications—metformin, naltrexone, and bupropion—before switching her to semaglutide when it became available. Over time, her patient lost 150 pounds and resolved her sleep apnea and diabetes. 


People qualify for obesity medications if they have a high body mass index (BMI) and an obesity-related condition, such as high blood pressure or high cholesterol. Jastreboff concludes the chapter by warning readers that these medications are not short-term solutions or “magic” pills that are guaranteed to work the same for everyone. She reiterates that if the risk of leaving someone’s obesity untreated outweighs the risk of the medications, medications could be a solution, but she does not offer detailed data or counterpoints that could cast her medications in a less favorable light.

Chapter 7 Summary & Analysis: “No More New Year’s Resolutions: Treating Obesity to Optimize Health”

Jastreboff always asks her patients why they want to lose weight. Their answers help her understand their personal experiences and goals. She believes that there is no “finish line” in treating obesity and that practitioners must be focused on lifelong care and communicate that expectation to the patient as well. She laments that many people attach huge importance to the numbers they see on the scale or their clothes but don’t know about the Enough Point that their biology is constantly pursuing. For instance, at over 200 pounds, a patient named Shayna hated the number on the scale, wishing that she could go back to the 150 pounds she had been over 20 years earlier.


After learning about her patients’ goals, Jastreboff always reacts the same way. She calculates if their goal weight could be a healthy one for them, using the BMI metrics. She then tries to give the patient a “reasonable outlook” to manage their expectations. Everyone has different notions of what their ideal body weight is, and Jastreboff includes them in the decision-making about their treatment plan. Setting a “goal weight” is not merely about the number that patients would like to see on the scale but includes considering their ethnicity, gender, health conditions, and more. Jastreboff hopes that with more research, doctors will be able to develop a more exact “treat-to-target strategy” (160). Jastreboff does not, however, address some of the controversies around BMI, as some medical experts have recently questioned whether or not it is the most useful or accurate metric to use when assessing weight and health (Byker Shanks, Carmen, et al. “BMI or Not to BMI? Debating the Value of Body Mass Index as a Measure of Health in Adults.” International Journal of Behavioral Nutrition and Physical Activity, 25 Feb. 2025). 


Jastreboff and her patients also discuss the many benefits that improving one’s health can bring: better sleep, less pain, healthier organ function, and much more. Overall health is always influenced by both “nature,” or genetics, and “nurture,” or environment. We all live in an environment that promotes obesity, but because of our differences, not everyone develops it. While medication can help people’s weight loss, it cannot bring the benefits of exercise and high-quality food, which Jastreboff always prescribes along with the medications. Stress management and improving sleep are also essential. 


She argues that losing weight must be reimagined as a lifestyle change with qualitative improvements, not simply as a changing number on the scale or clothing size. She often leaves the number reduction up to the medication and collaborates with the patient to, bit by bit, make changes to their overall health. For example, many patients engage in “clean” eating for certain periods of time, but when they break their rules, they revert back to their old habits. Instead, people should have a balanced and realistic approach to eating. Jastreboff’s acknowledgement of the importance of lifestyle changes and permanent dietary changes somewhat contradicts her earlier assertions regarding the relative difficulty of relying on “willpower” and the efficacy of non-medication tactics. Even so, her analysis here suggests that major lifestyle changes are still essential, even with the medications. This stance raises the question of how essential such medications really are if lifestyle factors can make such a dramatic difference and are mandatory either way. 


Jastreboff uses the acronym “SMART” (specific, measurable, achievable, relevant, and time-bound) to guide these strategies. For instance, one patient rarely exercised. Jastreboff identified jogging as an activity he enjoyed and prescribed it three times a week for 20 minutes, making this goal more achievable and specific than “everyday” or “whenever.” Jastreboff argues that it is crucial to overcome “all-or-nothing” thinking when it comes to health—however, her dichotomy of medications versus “willpower” earlier in the text arguably promoted such all-or-nothing thinking when considering techniques like calorie counting, making her views somewhat contradictory. Winfrey echoes her perspective, calling obesity medications one tool that people must combine with every other “tool” in their toolbox. 


Another important consideration is patients’ mental health. People with obesity may have depression, anxiety, or eating disorders such as binge eating. Jastreboff feels that without mental-health help, people’s quality of life may not improve even if they do lose weight. Some people have unrealistic expectations, hoping that their weight-loss medications will fix everything in their lives. Others may experience a sense of dissociation if they lose a lot of weight and don’t really recognize the person in the mirror anymore. She encourages people to work with a mental-health professional while undertaking the huge changes in lifestyle and medication that this treatment involves, but this advice does not consider the socioeconomic factors that might make accessing such support unaffordable for many patients.


Jastreboff laments the shortage of supply when it comes to obesity medications. These new treatments are not familiar and well understood to many doctors, who didn’t learn about them at medical school and may not have time to complete the insurance documents to prescribe them. Many people who want these medications are not covered by their insurance, and paying out of pocket is very expensive. Some people seek imitation treatments through telehealth or spa businesses. Jastreboff warns readers against seeking any kind of medication outside of the health-care system and medical supervision, noting that people have suffered terrible side effects from taking such pills. She hopes that the real, FDA-approved obesity medications will soon become cheaper and more accessible to people of all walks of life. 


Without access to these medications or other viable treatments, people may either cope with the risks and stresses of obesity or pursue other, less credible options. Jastreboff’s disappointment in people’s lack of access to obesity medications reflects her strong opinion about The Medical Necessity of Treating Obesity, but it should be considered in light of her own professional and financial ties to these particular medications.

Chapter 8 Summary & Analysis: “Freedom: ‘It’s Just as Easy to Lose Weight as It Ever Was to Gain Weight’”

Winfrey shares her astonishment at how much “food noise” dominated her mind for so many years, speaking to idea of Obesity as a Disease Versus Personal Failure. Without it, she feels sharper and more present in her life, a common experience among patients who lose weight with obesity medications. Jastreboff explains that narratives about weight loss are what dominate the scholarship and the social-media discourse about obesity medications but that there’s a lack of research about the “Weight Plateau Phase” that comes afterward. Jastreboff acknowledges that this research is just beginning and has offered only general knowledge so far of how these medications affect the body, which means that the effects of long-term usage—which Jastreboff advocates for—are not clearly known, complicating the risk assessment of the approach she promotes.


Jastreboff explains that reaching a weight plateau is a positive sign that your body has established a new Enough Point that, if you keep taking the medications, it will maintain. This is essential; after all, if the medication continued to make your body lose weight, you would eventually die. Patients’ weight plateaus are famously unpredictable, as some plateau around their goal weight, while others remain much heavier than they would like. Many patients expect to stop taking the medication once they have reached their new weight, but Jastreboff claims that ceasing the medication would prompt people to regain all their lost weight. 


While Jastreboff continues to invoke The Medical Necessity of Treating Obesity, she stresses that obesity medications are not a cure for obesity; they are a treatment. If they were a cure, people could stop using them and maintain their new, healthier weight. Patients can only expect to maintain their new weight if they continue treating the disease of obesity with these medications. This sometimes presents a problem, as patients may not have enough insurance coverage to pay for these medications long-term. Notably, Jastreboff does not yet fully acknowledge that serious side effects would have to be risked for years or decades; instead, she emphasizes the idea of financial strain and access, creating an unbalanced picture of the factors involved. 


More significantly, she also admits that sometimes patients begin to regain weight during the plateau phase even when they continue the medications. Jastreboff acknowledges that more research is needed to understand this phenomenon, but this factor undermines her earlier presentation of medications as somehow inherently superior to other treatments that do not rely on medications. While she criticized such treatments and techniques as often failing to result in permanent weight loss, she does not apply the same disqualifying reasoning to the GLP-1s that she promotes, even though there is also a risk of gaining back weight, should patients choose to go this route. 


Jastreboff reports that losing weight has been proven to help alleviate numerous different health problems, such as cardiovascular issues, fatty liver, kidney disease, and knee osteoarthritis. She argues that teens and young people can benefit from early medical intervention, such as NuSHs and other medications, to address their obesity to avoid needing extensive treatment later in life, but she does not address what risk factors young people might be particularly susceptible to, especially considering the severity of some of the possible side effects. 


Jastreboff is excited that the continued SURMOUNT-1 Trial of tirzepatide addressed patients with prediabetes. The results suggest that when people with prediabetes take this medication, they do not develop full-blown diabetes. She hopes that this research continues and results in a medication that can prevent diabetes, a common and debilitating illness in the US. By pointing to the proven and significant benefits of weight loss, the author urges the readers to consider obesity as a serious disease that warrants treatment.


People who have positive experiences losing weight with obesity medications find joy in the simple pleasures that their weight made it difficult to enjoy: long walks, less joint pain, easy mobility, and buying clothes from regular stores. However, others have had more challenging or tumultuous experiences. One patient, James, used the medication as a treatment for his diabetes, pairing it with healthier foods and regular exercise. Over the course of a year and a half, he lost 90 pounds and, crucially, resolved his diabetes. James was bewildered and somewhat embarrassed by the great attention his colleagues paid to his weight loss. 


Jastreboff explains that this is a common experience since weight loss and gain is always visible to others. Some people may mean well, while others may feel jealous or even try to sabotage patients’ success. Many patients find that their self-image changes as they feel better and experience new things. People’s friendships and marriages also often change, as their weight loss and other personal changes may shift the dynamics in their relationships.

blurred text
blurred text
blurred text

Unlock all 52 pages of this Study Guide

Get in-depth, chapter-by-chapter summaries and analysis from our literary experts.

  • Grasp challenging concepts with clear, comprehensive explanations
  • Revisit key plot points and ideas without rereading the book
  • Share impressive insights in classes and book clubs